CancerDrs Find care

Multiple Myeloma clinical trials in Massachusetts

56 actively recruiting multiple myeloma trials at 10 sites across Massachusetts.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Mercy Medical Center — Springfield, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …

Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Massachusetts:
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
  • BIDMC Research Pharmacy — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…

Sponsor: Celgene
NCT ID: NCT05519085
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…

Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Boston Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…

Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Massachusetts:
  • Beth Israel Deaconess Medical Center /ID# 271535 — Boston, Massachusetts
  • Dana-Farber Cancer Institute /ID# 261554 — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Massachusetts:
  • UMass Memorial Medical Center — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …

Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
  • Research Site — Boston, Massachusetts
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …

Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in Massachusetts:
  • GSK Investigational Site — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in Massachusetts:
  • Boston Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period o…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06232044
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…

Sponsor: Sanofi
NCT ID: NCT06356571
Sites in Massachusetts:
  • Beth Israel Deaconess Medical Center - Boston- Site Number : 8400005 — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and ne…

Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT02343042
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…

Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be a…

Sponsor: Multiple Myeloma Research Consortium
NCT ID: NCT06171685
Sites in Massachusetts:
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
  • Dana Farber Cancer Institute/Harvard Medical School — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multipl…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06083922
Sites in Massachusetts:
  • Tufts Medical Center (Data Collection Only) — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants …

Sponsor: AstraZeneca
NCT ID: NCT06106945
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06140524
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05372354
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →

Showing 25 of 56 trials with sites in Massachusetts. See all multiple myeloma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20